Mark T Mclaughlin

US Patent:

6747930, Jun 8, 2004

Filed:

Sep 29, 1998

Appl. No.:

09/163087

Inventors:

James Weldon - Boulder CO
Hilary S. Lackritz - Cupertino CA
Jerry Smith - Littleton CO
Mark McLaughlin - Baton Rouge LA
J. Bradford Merry - Annapolis MD

Assignee:

Hide Seek Technologies, Inc. - Akron CO

International Classification:

G11B 700

US Classification:

369 5321, 369 471, 369 84

Abstract:

A method and system is disclosed for purposefully modifying the accessibility of information encoded upon an optical medium for indicating a state or history of the optical medium and/or a state or history of an item associated therewith. In one embodiment, the optical medium is purposefully damaged when the information is initially accessed so that upon subsequent access attempts of the information on the optical medium, a previous access of the information is detected by the purposefully induced errors. Thus, there is provided an effective technique for limiting illegal duplication and/or use of, e. g. , software, movies, and music on compact disks and digital versatile disks. The present invention provides verification of persons and/or financial transaction cards during financial transactions. In another embodiment, a compact data storage device is disclosed having the approximate dimensions of a credit card that is capable of storing large amounts of data (e. g. , 50-100 Megabytes).

US Patent:

20100216992, Aug 26, 2010

Filed:

Feb 27, 2008

Appl. No.:

12/528689

Inventors:

Mark L. McLaughlin - Tampa FL, US

Assignee:

UNIVERSITY OF SOUTH FLORIDA - Tampa FL

International Classification:

C07D 409/04
C07D 403/14

US Classification:

544357

Abstract:

The present invention generally relates to compositions including six membered heterocyclic 1,4-diaza-2-one moieties covalently bonded by a hydrazine bond and processes for producing the same. The compositions of the present invention may be utilized as peptido- and/or proteomimetics, for example,' in connection with alpha-helical proteins, like Bcl-2 proteins.

US Patent:

20130065837, Mar 14, 2013

Filed:

Mar 21, 2011

Appl. No.:

13/636010

Inventors:

Lori Hazlehurst - Ruskin FL, US
Mark Mclaughlin - Tampa FL, US
Priyesh Jain - Tampa FL, US
William S. Dalton - Temple Terrace FL, US

Assignee:

UNIVERSITY OF SOUTH FLORIDA - Tampa FL

International Classification:

A61K 38/12
C12N 5/09
C07K 7/54
A61P 35/00

US Classification:

514 199, 435375, 530317

Abstract:

Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.

US Patent:

20220282215, Sep 8, 2022

Filed:

May 24, 2022

Appl. No.:

17/752481

Inventors:

- Tampa FL, US
Mark McLaughlin - Tampa FL, US
Hao Liu - Tampa FL, US

International Classification:

C12N 5/0783
A61K 39/00
A61K 35/12
G01N 33/50

Abstract:

Disclosed are compositions and methods for ex vivo expansion of tumorinfiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumorinfiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.

US Patent:

20190177693, Jun 13, 2019

Filed:

Feb 11, 2019

Appl. No.:

16/272524

Inventors:

- Tampa FL, US
Mark McLaughlin - Tampa FL, US
Hao Liu - Tampa FL, US

International Classification:

C12N 5/0783
G01N 33/50
A61K 39/00

Abstract:

Disclosed are compositions and methods for ex vivo expansion of tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor-infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.

US Patent:

20170081635, Mar 23, 2017

Filed:

Mar 20, 2015

Appl. No.:

15/126436

Inventors:

- Tampa FL, US
Mark McLaughlin - Tampa FL, US
Hao Liu - Tampa FL, US

International Classification:

C12N 5/0783
G01N 33/50
A61K 39/00

Abstract:

Disclosed are compositions and methods for ex vivo expansion of tumorinfiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumorinfiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.